- Home
- BLNK vs EQ Comparison
BLNK vs EQ Comparison
Compare BLNK & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLNK | EQ |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.9M | 129.0M |
| IPO Year | 2008 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BLNK | EQ |
|---|---|---|
| Price | $0.56 | $2.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $2.33 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.0M |
| Earning Date | 05-08-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $126,197,000.00 | $41,095,000.00 |
| Revenue This Year | $5.71 | N/A |
| Revenue Next Year | $19.65 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.36 |
| 52 Week High | $2.65 | $3.54 |
Technical Indicators
Market Signals| Indicator | BLNK | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 35.43 | 39.63 |
| Support Level | $0.54 | $1.68 |
| Resistance Level | $0.72 | $2.61 |
| Average True Range (ATR) | 0.04 | 0.28 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 14.07 | 0.94 |
Price Performance
Historical ComparisonAbout BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from the U.S.A.
About EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.